Invivoscribe | Personalized Molecular Medicine

Notice: Acute Myeloid Leukemia (AML) The FDA has made it clear that a FLT3 companion diagnostic is required for approval of any FLT3-targeted or FLT3-stratified therapy. LabPMM is the only clinical laboratory with access to the patents required to develop and offer a FLT3 companion diagnostic for worldwide use(excluding Japan).

Personalized Medicine & IVS
Invivoscribe is a leading provider of clinically-validated CE-marked in vitro diagnostic products. Through our subsidiary, LabPMM, we provide worldwide access to molecular biomarker testing, which enables pharmaceutical companies to bring to the market new targeted treatments, and allows physicians to better determine optimal treatment for their patients.

Research & Biotechnology
Development & Partnering
Companion Diagnostics

Invivoscribe develops revolutionary approach to manage biomarkers and associated licenses
This technology will simplify licensing, increase access to biomarker testing, while ensuring the ongoing strength and value of intellectual property around biomarkers. We believe the approach will be embraced by all stakeholders.

CE-marked TCRG Gene Rearrangement Assay 2.0

This in vitro diagnostic assay, which is available for sale and use only outside North America, detects the vast majority of clonal T cell receptor gamma gene rearrangements with a single multiplex master mix, generates a single Gaussian distribution in a size range consistent with testing FFPE specimens, and comes with software that assists with objective interpretation. Contact us or visit our online catalog to learn more.

TCRG Gene Rearrangement Assay 2.0

Our improved assay detects the vast majority of clonal T cell receptor gamma gene rearrangements with a single multiplex master mix, and generates a single Gaussian distribution in a size range consistent with testing FFPE specimens. Contact us or visit our online catalog to learn more.

BCR/ABL Lyophilized Cell Controls and RNA Dilution Sets are available

We have released our BCR/ABL b3a2, b2a2, and e1a2 Lyophilized Cell Controls and RNA Dilution Sets.

In the News

May 15, 2012 USPTO
United States Patent No. 8,178,292 issued on May 15, 2012. This patent further consolidates our already dominant intellectual property around the detection of FLT3-ITD mutations

December 26, 2011 The New York Times
A Push to Tie New Drugs to Testing by Andrew Pollack

February 23, 2011 Pharmacogenomics Reporter
Novartis, Invivoscribe to Develop Companion Test for Acute Myeloid Leukemia Rx Midostaurin

February 21, 2011 BioCentury
Invivoscribe Technologies Inc., Novartis deal

Press Releases
February 15, 2011
Invivoscribe Announces Collaboration Agreement to Develop Companion Diagnostic

Our growth continues... and continues...

We doubled space at our San Diego headquarters in 2011, building out two additional suites for cGMP manufacturing and shipping. In April 2012 we expanded into another adjacent suite to secure offices for management personnel. LabPMM LLC expanded into dedicated space San Diego in 2011, and LabPMM GmbH, located in Martinsried, Germany, started the move into our brand new European reference laboratory in September 2011. Personnel were hired and completed training at our San Diego facility, and we anticipate completion of assay validation and the start of clinical testing in 2Q2012.

View all News